A kit for predicting, preventing and treating myopia

By detecting the AREG protein content in tears, the high cost and cumbersome nature of existing myopia detection methods have been solved, enabling simple and efficient myopia screening and treatment.

CN114384254BActive Publication Date: 2024-11-26JINSHAN HOSPITAL AFFILIATED TO FUDAN UNIV (EYE DISEASE PREVENTION & TREATMENT CENT OF JINSHAN DISTRICT RES CENT FOR CHEM INJURY EMERGENCY & CRITICAL MEDICINE OF SHANGHAI MUNICIPAL HEALTH COMMISSION)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210065494.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-20
Publication Date
2024-11-26
Estimated Expiration
2042-01-20

AI Technical Summary

Technical Problem

Existing methods for detecting myopia are either costly or involve cumbersome testing processes, making them difficult to widely apply in schools, communities, and primary care hospitals.

Method used

Using AREG protein in tears as the sole biomarker, myopia can be predicted by detecting AREG protein levels in tears, and specific detection agents and AREG inhibitors can be used for diagnosis and treatment.

Benefits of technology

It simplifies the myopia detection process, reduces costs, improves operability and patient acceptance, and provides a simple and efficient screening and treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114384254B_ABST
    Figure CN114384254B_ABST
Patent Text Reader

Abstract

The present invention relates to a kit for predicting and preventing myopia, and the kit comprises a reagent for detecting the AREG content in tears and / or an AREG antibody. The present invention provides a myopia assessment marker, and clinical experiments show that the AREG concentration in the tears of myopic patients is significantly higher than that of the non-myopic group, and the AREG concentration in the tears is significantly negatively correlated with the equivalent spherical lens; significantly positively correlated with the axial length; and significantly positively correlated with the axial ratio ratio. The FDM model shows that the injection of AREG antibodies into the vitreous cavity can inhibit the development of myopia, and supplementing exogenous AREG promotes the progression of myopia. The advantages are as follows: the present invention proposes for the first time to use tears as a test specimen, and whether a patient is myopic can be predicted by detecting the AREG content in tears. Compared with the prior art, the operation is simple, non-invasive detection and treatment can be achieved, and the effect is better, and there is a good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, in particular to a kit for predicting, preventing and treating myopia. Background Art

[0002] Myopia is a refractive error caused by the mismatch between the growth and development of the eye axis and the refractive power of the eyeball, which causes the imaging of external objects in front of the retina. The growth and development of the eyeball is inseparable from the secretion of signal molecules and the activation and regulation of related signal pathways. At present, the monitoring of myopia degree mainly relies on physical measurement methods of biological parameters such as axial length, refractive power, fundus condition, etc., and there is no clear molecular marker related to the degree of myopia for clinical application. The collection of tear samples is a convenient, non-invasive and rapid method that can be widely used in clinical practice. At present, there are few studies on whether there are biological signal molecules related to myopia in tears. The present invention finds for the first time that measuring the protein content of AREG in tears may be used as a marker to predict the effect of myopia control, and the preparation of AREG antibodies may provide new targets for clinical medication of myopia.

[0003] Chinese patent application: CN201480018884.1 discloses an accommodative contact lens, which includes a variable focus optical module, the optical module includes an optical chamber and one or more eyelid engagement chambers coupled to the optical chamber using one or more extensions, the extension including a channel extending between the optical chamber and the one or more eyelid engagement chambers. The module may include a self-supporting module that can support itself before being placed in the contact lens to facilitate placement before being encapsulated in the contact lens. The module may include one or more light-transmitting materials to provide improved optical correction and may be combined with soft contact lens materials such as hydrogels. In many embodiments, the module includes a support structure extending between an upper membrane and a lower membrane to accurately provide variable refractive power with reduced distortion, and to provide improved responsiveness to pressure caused by the eyelids. Chinese patent application: CN101892306A discloses a kit for detecting pathological myopia, including optional related reagents for detecting BAI3 gene rs2073135 variation, CCDC149 gene rs4697489 variation, rs248014 variation, rs1105191 variation, rs1943049 variation or / and TNC gene rs7035322 variation for pathological myopia screening, and predicting the susceptibility of the subject to pathological myopia by determining whether there are variation in the six SNP sites of rs2073135, rs4697489, rs248014, rs1105191, rs1943049 and rs7035322 of the subject.

[0004] However, it can be seen from the contents of the above two patent documents that the prior art either uses relevant medical instruments to detect and treat myopia, or predicts myopia by detecting multiple SNP site variations, which has the defects of high cost or complicated detection methods.

[0005] In view of this, the present invention innovatively proposes a marker for predicting myopia for the first time. In the detection process, only the patient's tears need to be taken as a specimen, and the AREG content in the tears can be detected to predict whether the patient is myopic. The method of the present invention is simple to operate, low in cost, and effective, which greatly improves the patient's acceptance. There is no report on the kit for predicting and preventing myopia of the present invention. Summary of the invention

[0006] The purpose of the present invention is to provide a kit for predicting and preventing myopia in view of the deficiencies of the prior art.

[0007] To achieve the above object, the technical solution adopted by the present invention is:

[0008] In a first aspect, the present invention provides the use of tear AREG protein as a marker in the preparation of a detection product for predicting myopia.

[0009] Preferably, the detection product detects tears.

[0010] Preferably, tear AREG protein is used as the only marker.

[0011] Preferably, the detection product is a diagnostic kit.

[0012] In a second aspect, the present invention provides a kit for predicting myopia, wherein the kit comprises a reagent for specifically detecting tear AREG protein.

[0013] In a third aspect, the present invention provides the use of tear AREG inhibitors in the preparation of drugs for treating myopia.

[0014] Preferably, the inhibitor is selected from small molecule compounds or biomacromolecules.

[0015] Preferably, the biomacromolecule is a small interfering RNA, dsRNA, shRNA, microRNA, antisense nucleic acid that has tear AREG protein or its transcript as the target sequence and can inhibit tear AREG protein expression or gene transcription; or a construct that can express or form the small interfering RNA, dsRNA, microRNA, antisense nucleic acid.

[0016] Preferably, the drug contains a safe and effective dose of AREG antibody and a pharmaceutically acceptable carrier.

[0017] In a fourth aspect, the present invention provides a method for evaluating myopia for non-diagnostic and non-therapeutic purposes, wherein the method uses the tear AREG protein content as a biomarker.

[0018] The present invention has the advantages that:

[0019] 1. The present invention has discovered for the first time through clinical experiments and animal experiments that AREG protein in tears can be used as a highly operable myopia diagnostic marker. The present invention assists in clinical myopia screening and prevention and control, and is applied in clinical screening, diagnosis and follow-up of myopia. The current technology uses subjective optometry, measurement of axial length and other myopia diagnostic methods, which have the disadvantages of being time-consuming, requiring high optometry, and expensive machinery and equipment, making it difficult to carry out screening in schools, communities, and primary hospitals. In the present invention, the doctor only needs to take the patient's tears as a specimen, and then detect the AREG content in the tears to predict whether the patient is myopic. The method is simple and efficient, highly operable, and has better diagnosis and treatment effects. AREG inhibitors can be used as drugs to treat myopia in clinical practice, which reduces the patient's treatment burden, while also improving the patient's acceptance, and is very practical.

[0020] 2. There are few studies on the related proteins in tears to predict and treat myopia in the prior art. From the content reported in the existing literature, it can be seen that most of them are from the perspectives of aqueous humor, vitreous body, cornea, etc. to achieve the effect of research and treatment of myopia, but these are invasive methods. They have certain research significance in animal experiments, but there are huge limitations in clinical sample research, difficult operation, poor feasibility, and cannot be applied to clinical experiments such as large clinical samples, before and after controls, and long-term follow-up. The present invention proposes for the first time to study myopia from the perspective of tears, and verifies its technical effects through relevant experiments. This is undoubtedly an innovative progress in this field. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Attached Figure 1 The tear concentration of AREG in myopia and emmetropia groups in clinical trials and the correlation between AREG and biometric parameters.

[0022] Attached Figure 2 It is the change of refraction and axial length (AL) of each group in animal experiments. DETAILED DESCRIPTION

[0023] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0024] Example 1 Clinical Trial

[0025] 1 Method

[0026] Clinical subjects were recruited and subjected to subjective refraction with a comprehensive ophthalmometer and axial length measurement with an IOL-master. Tears from both eyes were collected with a schirmer test strip (collection time was 5 min) and then quickly immersed in an EP tube containing 500 μL protein lysis solution (BC3710; Beijing Solebow Technology Co., Ltd., China) and stored at -20°C. The AREG protein concentration in each sample was subsequently detected by ELISA.

[0027] Inclusion criteria: Age 18-40 years old, corrected visual acuity 1.0, anisometropia ≤ 1.50D

[0028] Exclusion criteria: systemic diseases, history of long-term medication, history of eye surgery, ocular surface diseases, ocular inflammation, laser surgery, etc.

[0029] Group: Myopia group (equivalent spherical lens -0.5 to -6.0D)

[0030] Emmetropia group (spherical equivalent +0.5 to -0.5D)

[0031] Examination method: The refractive power of the subjects in the non-mydriatic state was measured by an automatic ophthalmometer (RK-F1, Canon, Japan), and the equivalent spherical lens was recorded as spherical lens power ± 1 / 2 cylindrical lens power. The axial length (AL) and corneal curvature (CR) of the subjects were measured using IOL master 500 (Zeiss, Germany), and the axial length / corneal curvature was recorded as the axial ratio ratio (AL / CR).

[0032] ELISA: AREG concentration was detected using human AREG-ELISA kit (ml025977-C, Shanghai ELISA Biotechnology Co., Ltd., China). The steps are as follows:

[0033] 1. Take out the required strips from the aluminum foil bag after equilibration at room temperature for 60 minutes, and seal the remaining strips in a ziplock bag and place them back at 4°C;

[0034] 2. Set up standard wells and sample wells, and add 50 μL of standards of different concentrations to each standard well;

[0035] 3. Add 50 μL of the sample to be tested to the sample well; do not add any to the blank well;

[0036] 4. Except for the blank wells, add 100 μL of horseradish peroxidase (HRP) labeled detection antibody to each well of the standard well and sample well, seal the reaction wells with a sealing film, and incubate in a 37°C water bath or incubator for 60 min;

[0037] 5. Discard the liquid, pat dry on absorbent paper, fill each well with washing solution (350μL), let stand for 1 min, shake off the washing solution, pat dry on absorbent paper, and repeat this washing process 5 times (you can also use a plate washer to wash the plate);

[0038] 6. Add 50 μL of substrate A and B to each well and incubate at 37°C in the dark for 15 min;

[0039] 7. Add 50 μL of stop solution to each well and measure the OD value of each well at a wavelength of 450 nm within 15 minutes.

[0040] 2 Results

[0041] See Figure 1 The AREG concentration in tears of myopic patients was significantly higher than that in the non-myopic group, and the AREG concentration in tears was significantly negatively correlated with the equivalent spherical lens; significantly positively correlated with the axial length; and significantly positively correlated with the axial ratio.

[0042] Example 2 Animal Experiment

[0043] 1 Method

[0044] Two-week-old male tricolor guinea pigs were divided into a normal group and a myopia group. The form deprivation myopia (FDM) model was induced in the myopia group by covering the right eye. Starting from the third week of covering, AREG antibody (FDM+anti-AR), AREG exogenous protein (FDM+AR), and PBS (FDM+vehicle) were injected into the vitreous cavity once a week for 2 weeks. The refractive power and axial length of each group were measured before and after the experiment.

[0045] FDM model induction method: 2-week-old male tricolor guinea pigs were raised in a natural light environment. The guinea pigs were fitted with a headgear made of a translucent balloon to cover the right eye, while the left eye was uncovered and exposed normally to ensure that the guinea pigs' limb movements, eating, head rotation and other movements were not affected.

[0046] Measurement of biological parameters: Tropicamide eye drops were applied 4 times at 5-minute intervals, and then the guinea pigs were subjected to strip retinoscopy using a strip retinoscope (YZ24; Suzhou Liuliu Vision Technology Co., Ltd., China), and the final result was the average of the 3 readings. After corneal anesthesia, ophthalmic A-ultrasound (OD1-AP, Kaixin Ultrasound, China) was used to measure the axial length of the guinea pigs, and the final result was the average of 10 measurements.

[0047] 2 Results

[0048] See Figure 2 In the FDM model, intravitreal injection of AREG antibody inhibits the development of myopia, while supplementation of exogenous AREG promotes myopia progression.

[0049] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the principle of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A method for detecting AREG protein for non-diagnostic purposes, characterized in that: Tears were used as test samples.